Olaris, Inc. Identifies Plasma Metabolic Signature to Classify Male...
Olaris has identified a metabolic signature within plasma that differentiates male patients with the LRRK2 heritable Parkinson's Disease (PD) from male patients with no PD diagnosis.(PRWeb February 14, 2022)Read the full story at https://www.prweb.com/releases/olaris_inc_identifies_plasma_metabolic_signature_to_classify_male_lrrk2_parkinsons_disease_patients/prweb18494592.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news
More News: Parkinson's Disease | Pharmaceuticals